NextCure, Inc. — Regulatory Filings 2024

Mar 21, 2024

Item 2.02. Results of Operations and Financial Condition

On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure

Beginning on March 21, 2024, the Company will be hosting calls with members of the investment community, which may reference presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.2.

The information furnished in this Item 7.01 (including Exhibit 99.2) shall not be deemed to be “filed” for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

​ ​	​
Exhibit No.	​	Description
99.1	​	Press release issued by NextCure, Inc. dated March 21, 2024
99.2	​	NextCure, Inc. P resentation dated March 21, 2024
104	​	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEXTCURE, INC. ​
By:	/s/ Steven P. Cobourn
Name:	Steven P. Cobourn
Title:	Chief Financial Officer